Ocugen, Inc.

Ocugen Inc's next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Ocugen Inc has 339.04M shares outstanding.

As of June 30, 2026, Ocugen Inc maintains a current ratio of 0.80, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -531.44, indicating conservative leverage, while an interest coverage ratio of -7.96 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -92.03, reflecting losses generated across the asset base. The company generates approximately 36,197.51 in revenue per employee across its workforce of 110.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Ocugen Inc generated 4.01M in revenue and converted that into -71.61M in net income, yielding earnings per share of -0.22. EBITDA reached -58.80M, while operating income came in at -60.31M.

As of June 30, 2026, Ocugen Inc holds 87.57M in cash and equivalents against 77.01M in total debt, resulting in a net debt position of -13.95M. Total book value stands at -14.49M, with working capital of -23.07M providing operational flexibility.

Ocugen Inc produced -53.28M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -133,920.90 in capital expenditures, free cash flow totaled -53.41M - equivalent to -0.17 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,504.43 and net profit margin of -1,786.27 provide insight into operational efficiency.

Ocugen Inc's most recent stock split took place on September 30, 2019 with a 60:1 split ratio.